Drug Profile
Research programme: macrocyclic therapeutics - Gilead/Spexis
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Gilead Sciences; Polyphor
- Developer Gilead Sciences; Spexis
- Class Macrocyclic compounds
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Unspecified in Switzerland
- 10 Aug 2016 Polyphor and Gilead agree to co-discover and co-develop macrocyclic therapeutics in Switzerland
- 10 Aug 2016 Early research in Undefined indication in Switzerland (unspecified route)